Abstract 1485P
Background
Patients (pts) diagnosed with metastatic cancer often experience a high symptom burden and diminished health-related quality of life (HRQOL), which can significantly impact their overall well-being. Physical activity (PA) has emerged as a promising intervention to alleviate symptoms and improve HRQOL in this population. This study examines the effects of a 12-week supervised remote PA program on symptom burden and health-related quality of life (HRQOL) in pts diagnosed with metastatic cancer.
Methods
This prospective study included eligible pts undergoing treatment for metastatic cancer. Initial assessments and weekly exercise guidance were provided to pts via WhatsApp. Proper home exercise techniques were demonstrated using the Vedius platform. The prescribed exercise regimen entailed 3 to 5 hours per week (4 to 6 days a week) of combined resistance and aerobic exercises. Outcome measures, including symptom burden (Edmonton Symptom Assessment System, ESAS, scale 0-90) and overall quality of life (Functional Assessment of Cancer Therapy-General, FACT-G, scale 0-108) were evaluated at baseline and after 12 weeks. Data analysis involved descriptive statistics and the linear mixed models.
Results
A total of 62 pts, with a median age of 68 years (range: 32-88), were enrolled in the study. Among the participants, 54.8% were female, 66.1% were white, and 61.3% were married, with 57.7% holding a college degree. The most prevalent cancer types included breast (24.2%), genitourinary (19.4%), lung (14.5%), and gynecological (14.5%). Over the study period, a significant improvement was observed in symptom burden (baseline mean=21.7, follow-up mean=7.8, P=0.001) and HRQOL (baseline mean=83.4, follow-up mean=95.4, P=0.001).
Conclusions
Our findings demonstrates that a 12-week supervised remote PA program has a significant positive impact on symptom burden and HRQOL in pts with metastatic cancer undergoing treatment. These findings underscore the potential benefits of incorporating PA interventions into the management of metastatic cancer, offering a promising avenue for improving patient outcomes and well-being.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10